ArticleIndian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine2020
Cytokine Storm in Novel Coronavirus Disease (COVID-19): Expert Management Considerations.
Article in Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Association of ulinastatin with 28-day mortality across different severities of viral pneumonia: a multicenter propensity score-matched study.Frontiers in pharmacology · 2026Article
- Relationship of Circulatory Markers of NETosis with COVID-19 Severity: A Prospective Cohort Study.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025Article
- Neurological manifestations of COVID-19 and its vaccines: an updated comprehensive review with an insight into pathophysiology.Annals of medicine and surgery (2012) · 2025Review
- A successful response to the second wave of COVID-19 in the slums of Delhi.Journal of global health · 2025Article
- Late pandemic COVID-19 positivity at the time of thrombectomy is associated with poor outcomes and tandem carotid pathology.Frontiers in neurology · 2025Article
- Efficacy of Ulinastatin in the Treatment of COVID-19: A Retrospective Study.International journal of general medicine · 2024Article
- Effect of extracorporeal hemoadsorption in critically ill patients with COVID-19: A narrative review.Frontiers in immunology · 2023Review
- Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review.Frontiers in pharmacology · 2023Review
- Potential protective effects of Huanglian Jiedu Decoction against COVID-19-associated acute kidney injury: A network-based pharmacological and molecular docking study.Open medicine (Warsaw, Poland) · 2023Article
- Utility of Biochemical Markers in Predicting Severe COVID-19: Experience from a Tertiary Hospital in South India.EJIFCC · 2022Article
- Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2022Article
- Clinical Characteristics and Outcomes of Patients Hospitalized with COVID-19 at Case Hospital, Uganda.Interdisciplinary perspectives on infectious diseases · 2022Article
- Comparison of Low-Versus High-Dose Steroids in the Clinical Outcome of Hospitalized COVID-19 Patients.Antibiotics (Basel, Switzerland) · 2021Article
- Cytokine Storm and Immunomodulation in COVID-19.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2021Article
- Use of CytoSorb therapy to treat critically ill coronavirus disease 2019 patients: a case series.Journal of medical case reports · 2021Article
- Review
- The Potential Use of Vitamin C to Prevent Kidney Injury in Patients with COVID-19.Diseases (Basel, Switzerland) · 2021Review
- Critical Care for COVID-19 Affected Patients: Updated Position Statement of the Indian Society of Critical Care Medicine.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2020Review
- Pathophysiological Mechanisms and Neurological Manifestations in COVID-19.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2020Article
- Current Approaches to COVID-19: Therapy and Prevention.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIM/OBJECTIVE/
introductionCytokine storm or cytokine release syndrome (CRS) is inevitable in severe and critically ill patients with novel coronavirus disease-2019 (COVID-19). This review aimed to discuss current therapeutic options for the management of CRS in COVID-19.
backgroundCytokine storm is caused by the colossal release of proinflammatory cytokines [e.g., IL (interleukin)-2, IL-6, IL-8 TNF (tumor necrosis factor)-α, etc.] causing dysregulated, hyperimmune response. This immunopathogenesis leads to acute lung injury and acute respiratory distress syndrome (ARDS). Targeting cytokine storm with the therapies that are already available in India with the support of published guidelines and consensus can assist in achieving a better outcome in COVID-19. REVIEW
resultsWe predominantly included published guidelines or consensus recommendations about the management of cytokine storm in COVID-19. From the existing literature evidence, it is observed that among the currently available agents, low-dose corticosteroids and heparin can be beneficial in managing cytokine storm. The use of serine protease inhibitors such as ulinastatin has been advised by some experts. Though therapies such as high-dose vitamin C and interleukin-6 inhibitors (e.g., tocilizumab) have been advised, the evidence regarding their use for cytokine storm in COVID-19 is limited. Therapies such as Janus kinase inhibitors (JAK) inhibitors and Neurokinin-1 receptor (NK-1) antagonists are still in research. Besides, pharmaceutical treatments, use of blood purification strategies, and convalescent plasma may be life-saving options in some of the critically ill COVID-19 patients. For these therapies, there is a need to generate further evidence to substantiate their use in CRS management.
conclusionCurrent management of COVID-19 is preventive and supportive. Different therapies can be used to prevent and treat the cytokine storm. More research is needed for further supporting the use of these treatments in COVID-19. HOW TO CITE THIS ARTICLE: Mehta Y, Dixit SB, Zirpe KG, Ansari AS. Cytokine Storm in Novel Coronavirus Disease (COVID-19): Expert Management Considerations. Indian J Crit Care Med 2020;24(6):429-434.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.